CONVERT II
Research type
Research Study
Full title
An Evaluation of the AeriSeal System® for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema: The CONVERT II Trial
IRAS ID
336595
Contact name
Pallav Shah
Contact email
Sponsor organisation
PulmonX Corporation
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
Emphysema causes destruction of the small airways in the lung, leading to lung over-inflation, difficulty taking up
oxygen, and breathlessness. This can often be improved by implanting a valve (called the Zephyr Valve) into the most
diseased part of your lung to improve your breathing. When the Zephyr Valve is implanted in the most diseased part of
your lung it stops inhaled air from getting to that part of the lung, but lets air out. This causes that part of the lung to
deflate, and as a result, the healthier part of the lung can function better, making breathing easier. Currently the Zephyr
Valve can only be inserted into the lung when there are no open air channels between the lung compartments where
the valve is situated. This means that patients who do have open air channels cannot currently have this valve inserted
to improve breathing. This study is testing the use of the AeriSeal System during a bronchoscopy procedure to see if it
is an effective technique to close the air channels between your lungs (we call it “fissure closure”) and remove the air
flow between your lung compartments. If the closure of the fissure is successful, your doctor can then perform the
Zephyr Valve Procedure to treat your emphysema symptoms. This study therefore combines both procedures (the
AeriSeal System and the Zephyr Valve) to improve breathing function.REC name
London - Westminster Research Ethics Committee
REC reference
24/LO/0094
Date of REC Opinion
26 Mar 2024
REC opinion
Further Information Favourable Opinion